| Tissue Specificity | Widely expressed. Highly expressed in pancreas, skeletal muscle, lung and brain. Expressed at intermediate level in kidney, liver and heart. |
| Post Translational Modifications | Aryl sulfonamide anticancer drugs, such as indisulam (E7070) or E7820, promote ubiquitination and subsequent degradation by the DCX(DCAF15) complex. RBM39 degradation results in splicing defects and death in cancer cell lines. Aryl sulfonamide anticancer drugs change the substrate specificity of DCAF15 by acting as a molecular glue that promotes binding between DCAF15 and weak affinity interactor RBM39. |
| Function | RNA-binding protein that acts as a pre-mRNA splicing factor. Acts by promoting exon inclusion via regulation of exon cassette splicing. Also acts as a transcriptional coactivator for steroid nuclear receptors ESR1/ER-alpha and ESR2/ER-beta, and JUN/AP-1, independently of the pre-mRNA splicing factor activity. |
| Protein Name | Rna-Binding Protein 39Caper AlphaCaperalphaHepatocellular Carcinoma Protein 1Rna-Binding Motif Protein 39Rna-Binding Region-Containing Protein 2Splicing Factor Hcc1 |
| Database Links | Reactome: R-HSA-72163 |
| Cellular Localisation | Nucleus SpeckleConcentrated In Nuclear SpecklesColocalizes With The Core Spliceosomal Snrnp Proteins |
| Alternative Antibody Names | Anti-Rna-Binding Protein 39 antibodyAnti-Caper Alpha antibodyAnti-Caperalpha antibodyAnti-Hepatocellular Carcinoma Protein 1 antibodyAnti-Rna-Binding Motif Protein 39 antibodyAnti-Rna-Binding Region-Containing Protein 2 antibodyAnti-Splicing Factor Hcc1 antibodyAnti-RBM39 antibodyAnti-HCC1 antibodyAnti-RNPC2 antibody |
Information sourced from Uniprot.org
